GlassScriptPhysician profile
Kevin D Tate
NPI 1437169729
$1,255.31
in general payments reported to CMS, 2019-2025
16 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2022: $11.71 · 2023: $361 · 2024: $266 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $472.63 | 2019-2023 | |
| Dexcom, INC. | $110.86 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Astellas Pharma US INC | $104.54 | 2023-2024 | Veozah |
| Pfizer INC. | $87.26 | 2019-2025 | |
| Lilly USA, LLC | $77.51 | 2022-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $64.36 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $62.74 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Valeritas, INC. | $59.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.45 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $42.14 | 2023-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $23.81 | 2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $21.63 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.71 | 2023 | Jardiance |
| Novo Nordisk INC | $18.47 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $17.87 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $15.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.